Cancer survivor, Gail Baron Simpson, shares her personal journey to treatment success in this in-depth interview with Precision Oncology specialist and CTOAM co-founder, Alex Rolland, and Michelle Morand, Precision Cancer Medicine Advocacy specialist and CTOAM co-founder.
Please watch our short intro video to Gail’s story first! 👉 • Introduction to Gail’s Incredible Can…
After being diagnosed with a rare orphan cancer, Gail discusses her experience with navigating the challenges of standard healthcare and her decision to hire CTOAM to help integrate Precision Cancer Medicine into her cancer care – and how she was able to advocate for the right treatment and eventually find success.
Join us for an extraordinary livestream webinar, ‘Paving the Way for the Future: Learning from 4 Biostasis Cases and the Challenges and Advancements at Tomorrow Bio’ featuring esteemed speakers Dr. Emil Kendziorra and Dr. Irishikesh Santhosh from Tomorrow Biostasis GmbH. This pivotal session, scheduled for March 18th, 2024, at 7:00 PM, will delve into the latest advancements and real-world applications of biostasis, focusing on the detailed processes and outcomes associated with four distinct patient cases from 2023.
In this webinar, we will explore the intricate procedures and challenges encountered during the biostasis process, including stabilization in the face of cardiopulmonary arrest, the nuances of surgical and perfusion procedures, and the critical cooldown process for long-term storage. Our experts will unpack the innovative techniques employed, the utilization of cryoprotectant solutions, cooling techniques, and the diligent monitoring through CT scans, alongside the resolution of unforeseen technical challenges.
Each case report offers a unique glimpse into the complexities of biostasis, presenting the issues faced, such as equipment malfunctions and procedural hurdles, and the subsequent strategies for resolution or planned mitigations. Through graphical presentations on temperature, pressure, and refractive index, and detailed analyses of CT scans, attendees will gain comprehensive insights into the cutting-edge methods and equipment pivotal to biostasis.
This webinar is not just a learning opportunity but a platform for interactive discussion. We encourage all attendees to engage with our speakers through live questions, share their insights, and participate in real-time polls. Whether you’re a seasoned medical professional, an avid student of science, or simply fascinated by the potential of biostasis to preserve life, this session promises to be both enlightening and engaging.
Mark your calendars for March 18th, 2024, at 7:00 PM, and prepare to be part of a groundbreaking exploration into the future of biostasis. Your participation and questions will enrich our collective understanding and foster a deeper discussion on the possibilities that lie ahead.
A computational model of the more than 26 million atoms in a DNA-packed viral capsid expands our understanding of virus structure and DNA dynamics, insights that could provide new research avenues and drug targets, University of Illinois Urbana-Champaign researchers report in the journal Nature.
“To fight a virus, we want to know everything there is to know about it. We know what’s inside in terms of components, but we don’t know how they’re arranged,” said study leader Aleksei Aksimentiev, an Illinois professor of physics. “Knowledge of the internal structures gives us more targets for drugs, which tend to focus on receptors on the surface or replication proteins.”
Viruses keep their genetic material —either DNA or RNA—packaged in a hollow particle called a capsid. While the structures of many hollow capsids have been described, the structure of a full capsid and the genetic material inside it has remained elusive.
The first UK patients received the experimental mRNA therapy – a type of immunotherapy treatment called mRNA-4359 – at Imperial College Healthcare NHS Trust as part of a phase 1/2 clinical trial. The trial aims to evaluate its safety and potential for treating melanoma, lung cancer and other ‘solid tumour’ cancers.
The treatment is designed using messenger RNA (mRNA) and works by presenting common markers of tumours to the patient’s immune system. This should help to train patients’ immune systems to recognise and fight cancer cells expressing these markers, but also potentially eliminate cells that may suppress the immune response.
The University of Chicago Medicine is among the first 30 institutions in the country to offer tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, immediately activating as an authorized treatment center after federal regulators approved the treatment on February 16, 2024.
TILs are…
Some patients with advanced melanomas — those that can’t be surgically removed or have spread to other parts of the body — don’t respond to standard treatment options such as immunotherapies and targeted therapies. TIL therapy gives these patients another therapeutic option: a completely personalized treatment made from the patient’s own cells that needs to be administered only once, since the cells remain in the body and keep performing their tumor-attacking duties.
Other cell therapies, such as CAR T-cell therapies, are currently approved only for blood cancers like leukemia. TIL therapy, which showed promising results in clinical trials, is the first FDA-approved cell therapy to treat solid tumors.
UChicago Medicine is helping lead continuing research into TILs even while offering the newly approved therapy to patients. Medical oncologists and scientists at the David and Etta Jonas Center for Cellular Therapy are currently studying TIL therapy for cervical cancer in a clinical trial, with plans to study TILs for even more tumor types in the future.
A new class of cancer treatments that harness the body’s immune system to fight tumors is being hailed as the biggest thing in oncology since CAR-T revealed the promise of cell therapy more than a decade ago.
There’s a growing pipeline of cancer therapy candidates that harness a patient’s immune system to fight tumors.
This year, Rockefeller scientists plumbed the depths of wound repair and tackled how songbirds solve problems; they used microchips to grow mini-lungs and proposed an environmental trigger for multiple sclerosis. Efforts to combat COVID, Hepatitis B, and other infections bore fruit, and countless papers shed light on basic research, answering questions that have long baffled biologists. Here are some of the intriguing discoveries that came out of Rockefeller in 2023.
As the male reproductive system ages, it becomes more and more susceptible to mutations. New research from the laboratory of Li Zhao explored this phenomenon in fruit flies, by focusing on how mutations arise during the formation of sperm. The team found that, while mutations are common in the testes of both young and old flies, the repair mechanisms that remove those mutations and maintain genomic integrity during spermatogenesis become less efficient in older individuals, leading to the accumulation and persistence of more mutations in older flies.
Thrombolytic therapy administered longer after the onset of ischemic stroke than current recommendations did not demonstrate improved clinical outcomes as compared to placebo, according to a recent trial published in the New England Journal of Medicine.
Minjee Kim, MD, associate professor in the Ken and Ruth Davee Department of Neurology’s Division of Neurocritical Care, was a co-author of the study.
Ischemic stroke occurs when a blood vessel supplying blood to the brain is blocked or reduced, and accounts for nearly 90% of all strokes, according to statistics from the American Stroke Association.
